- Two elephants die in flash flooding in northern Thailand
- Tunisia votes with Saied set for re-election
- Too hot by day, Dubai's floodlit beaches are packed at night
- A 'forgotten' valley in storm-hit North Carolina, desperate for help
- Italy targets climate activists in 'anti-Gandhi' demo clampdown
- US trade chief defends tariff hikes when paired with investment
- EU court blocks French ban on vegetable 'steak' labelling
- Meta AI turns pictures into videos with sound
- US dockworkers return to ports after three-day strike
- DR Congo to begin mpox vaccination campaign Saturday in east
- Meta must limit data use for targeted ads: EU court
- Oil extends gains, jobs report lifts Wall Street
- US hiring soars past expectations in sign of resilient market
- As EU targets Chinese cars, European rivals sputter
- Top EU court finds against FIFA in key transfer market ruling
- Oil extends gains, Hong Kong stocks resume rally
- 'A man provides': Ukrainian miners send families away as Russia advances
- EU states greenlight extra tariffs on EVs from China
- Hong Kong stocks resume rally, oil dips after Middle East-fuelled surge
- Crude stable after Israel-Iran surge, Hong Kong stocks resume gains
- Hera spacecraft to probe asteroid deflected by defence test
- US dockworkers to head back to work after tentative deal
- After Helene's destruction, North Carolina starts to rebuild
- Dockers end three-day strike at Montreal port
- What next for OpenAI after $157 billion bonanza?
- Israel-Hamas war causes 86-percent dive in Gaza GDP: IMF
- Milan's Morata moves house after Inter-fan town mayor 'violates' privacy
- 'Devastating' storm hits Augusta National but Masters will go on
- Relief in Brazil, Asia over delay to EU deforestation rules
- Oil prices jump, stocks fall on Middle East tensions
- Biden says 'discussing' possible Israeli strikes on Iran oil facilities
- Oil prices rise, stocks fall on Middle East tensions
- Oil rallies, stocks mostly retreat on Middle East tensions
- Phasing out teen smoking could save 1.2 mn lives: study
- 'Welcome relief': Asia producers hail EU deforestation law delay
- Japan PM slated to announce plans for 'happiness index'
- Turkish inflation falls less than expected in September at 49.4%
- Easing inflation lifts profit at UK supermarket Tesco
- Skiing calls on UN climate science to combat melting future
- China wine industry looks to breed climate resilience
- Tokyo rallies on weak yen, Hong Kong drops after surge
- Dutch airline KLM unveils 'firm' cost-cutting measures
- Carpe diem: the Costa Rican women turning fish into fashion
- Senegal looks to aquaculture as fish stocks dwindle
- Will AI one day win a Nobel Prize?
- Climate change, economics muddy West's drive to curb Chinese EVs
- Argentina's Milei vetoes university budget after huge protests
- TotalEnergies plans to grow oil and gas production until 2030
- 2024 Nobels offer glimmer of hope as global crises mount
- Tokyo rallies on weak yen, Hong Kong reverses after surge
Grief and outrage in Gambia over cough syrup deaths
When Wuri Bailo Keita's two-year-old daughter Fatoumatta developed a fever, he took her to hospital where she was diagnosed with malaria and sent home with a prescription for a paracetamol syrup.
Less than a week later she was dead.
The infant is just one of 69 Gambian children to die of acute kidney failure since July in a series of cases linked to four Indian-made cough syrups.
The widening scandal has highlighted flaws in the tiny West African nation's healthcare system, in turn raising questions about potential loopholes in world pharmaceutical trade.
"She could not eat anything and she was oozing blood from her mouth and nose", Keita, a 33-year-old carwash attendant, told AFP, recounting his daughter's suffering.
"At some point, I was praying for God to take her life."
President Adama Barrow made a nationwide address on Saturday after the police launched an inquiry and health authorities were told to suspend the import licence of a suspected company.
Barrow also promised to update drugs-related laws and praised the work of the health ministry in preventing further deaths.
But fear and anger are mounting, and the death toll is still rising.
"President Barrow should sack the health minister, but instead of sacking him, he was praising the minister," said Keita, the grieving father.
"We want justice for these children."
Social media has been swamped by criticism of the healthcare system and by photos of the children who have died, most of whom were aged under five.
"It's time for the government to step up and stop these products," Mariama Kuyateh, a 30-year-old mother who lost her son Musa in September, told AFP.
"If they don't, and other syrups enter the country, it will be terrible."
- No test lab -
The deaths were catapulted to global prominence last Wednesday when the UN's World Health Organization (WHO) issued an alert over four syrups made by Maiden Pharmaceuticals of India.
Lab tests found "unacceptable amounts" of diethylene glycol and ethylene glycol, the WHO said.
The toxic impact from these substances includes "acute kidney injury which may lead to death," the agency said.
The Gambian health authorities, after launching their own investigation in July, on September 23 ordered a recall of all medicines containing paracetamol or promethazine syrup.
They have cited E.coli bacteria as a possible cause of the deaths.
India's health ministry said late Thursday it had been informed of the WHO's findings last month and was awaiting the results of its own lab tests on the four drugs.
Maiden Pharmaceuticals was not licensed to distribute the four products in India and had only manufactured and exported them to The Gambia, it said.
"It is a usual practice that the importing country tests these imported products on quality parameters, and satisfies itself as to the quality of the products," the ministry said.
But The Gambia has no national laboratory to test for drug quality and food safety -- a lack that Barrow on Saturday vowed to redress.
Maiden Pharmaceuticals did not respond to AFP requests for comment after the WHO alert.
- 'Failed miserably' -
Domestic critics accuse Barrow of having failed to protect the public and standing by watchdogs who should have been sacked.
The opposition United Democratic Party (UDP) criticised Barrow's "five-minute address" to a "traumatised nation left to wonder what other pharmaceuticals are on the market that may be fake or unsafe for use."
Nancy Jallow, of an NGO called Global Bridges, said she was appalled that top officials such as Health Minister Ahmadou Lamin Samateh and the head of the Medicines Control Agency, Markieu Janneh Kaira, were still in their jobs.
"We signed a social contract with Adama Barrow and his number one role is to protect the most vulnerable, and he has failed miserably," she told AFP.
She also called for a total halt to pharmaceutical imports "until Gambia's government can build a facility that can test medications."
Others voices, including the Gambia Bar Association, have insisted that the inquiry be conducted by independent experts.
- Weak healthcare -
Behind the political row is the reality of a country deep in poverty lacking many of the safeguards that elsewhere are taken for granted.
The Gambia is the smallest country in continental Africa, and nearly half of its population lives below the poverty line, according to the World Bank.
The country ranks a mere 174th out of 191 countries on the UN Human Development Index.
Its already weak health institutions were hit hard by Covid, with a 2020 UN assessment saying the pandemic had "exposed the shortcomings in the nation's healthcare system".
The UN flagged limited expertise, a shortage of basic equipment and a chronic lack of health professionals.
According to World Bank data, The Gambia in 2019 had just 0.1 physicians per 1,000 people -- less than a twentieth of the numbers in Canada.
The Gambia's under-five mortality rate is 49.4 deaths per 1,000 live births, according to UNICEF, compared to 3.7 deaths in Germany and 4.4 in France.
L.Peeters--CPN